Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE versus EVEKEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE versus EVEKEO.
AMPHETAMINE vs EVEKEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphetamine is a central nervous system stimulant that promotes release of monoamines (dopamine, norepinephrine, and serotonin) from presynaptic terminals and inhibits their reuptake, leading to increased synaptic concentrations. It also reversibly inhibits monoamine oxidase (MAO) and may directly stimulate postsynaptic receptors.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
5-60 mg/day orally, divided into 2-3 doses; immediate-release: initial 5 mg once or twice daily, increase by 5 mg increments weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
None Documented
None Documented
Clinical Note
moderateAmphetamine + Torasemide
"Amphetamine may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAmphetamine + Tranilast
"Amphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateHydroxyamphetamine + Tranilast
"Hydroxyamphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateDextroamphetamine + Tranilast
"Dextroamphetamine may decrease the sedative activities of Tranilast."
Terminal elimination half-life: 10-13 hours (adults) for immediate-release formulations; prolonged to 12-14 hours in chronic use. Clinical context: Half-life correlates with duration of action; twice-daily dosing may be needed.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Primarily renal (70-80% as unchanged drug and metabolites); minor biliary/fecal (approximately 2-5%). Urinary pH-dependent: acidic pH enhances elimination, alkaline pH reduces it.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Category D/X
Category C
CNS Stimulant
CNS Stimulant